This is a multicenter, open-label, prospective one arm study to explore the efficacy and
safety of Avatrombopag in non-severe aplastic anemia. Patients meeting the inclusion and
exclusion criteria would be recruited. Treatment of Avatrombopag would be started with
20mg/day. The dosage would be increased by 20 mg/day every 2 weeks if the platelet count
remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L.
The dosage could range from 20mg/week to 60mg/day. All patients would receive treatment for
at least 6 months except that the platelet <20×10e9/L at the dosage of 60mg/day for 4 weeks
or the platelet ≥200×10e9/L at the dosage of 20mg/week for 2 weeks. The hematological
response rate and safety will be recorded and compared at every month after starting the
study treatment. The patients would be followed up for at least 6 months.